No Data
Q2 2024 Sangamo Therapeutics Inc Earnings Call
Earnings Call: Sangamo Therapeutics Extends Cash Runway Into 2025
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Roche Strikes New Deal With Sangamo to Tackle Alzheimer's
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript
Express News | Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M